Gastrointestinal stromal tumours (GIST) have an incidence of~ 1.2 per 105 individuals per
year in most countries. Around 80% of GIST have varying molecular changes, predominantly …

Receptor tyrosine kinases (RTKs), a category of transmembrane receptors, have gained
significant clinical attention in oncology due to their central role in cancer pathogenesis …

Highlights•This clinical practice guideline provides key recommendations on the
management of gastrointestinal stromal tumours.•Recommendations have been agreed …

There are more than 70 distinct sarcomas, and this diversity complicates the development of
precision-based therapeutics for these cancers. Prospective comprehensive genomic …

Gastrointestinal stromal tumours (GISTs) are rare tumours, with an estimated unadjusted
incidence of around 1/100 000/year [1]. This only covers clinically relevant GISTs, since, if …

Gastrointestinal stromal tumors (GIST) are the most common type of soft tissue sarcoma that
occur throughout the gastrointestinal tract. Most of these tumors are caused by oncogenic …

Gastrointestinal stromal tumors (GISTs) are potentially malignancies that can occur
anywhere in the digestive tract. Tyrosine kinase inhibitors (TKIs) such as imatinib have …

Compared with traditional therapies, targeted therapy has merits in selectivity, efficacy, and
tolerability. Small molecule inhibitors are one of the primary targeted therapies for cancer …

Gastrointestinal stromal tumors (GIST) are rare neoplasms arising from the interstitial cell of
Cajal in the gastrointestinal tract. Two thirds of GIST in adult patients have c-Kit mutation and …

Sarcomas include diverse mesenchymal neoplasms with widely varied prognosis, clinical
behavior, and treatment. Owing to their rarity and histologic overlap, accurate diagnosis of …